港股異動 | 莎普愛思(603168.SH)競價漲停 現漲幅收窄至6% 實際控制人將變更
格隆匯2月27日丨莎普愛思(603168.SH)競價漲停,開盤後漲幅收窄至5.96%,報9.42元,暫成交7683萬元,最新總市值30.39億元。莎普愛思昨晚公告,陳德康簽署股份轉讓協議及表決權放棄承諾函,放棄其所持公司剩餘21.73%公司股份之上的表決權。同時,陳德康還將於2021年將其所持5.43%公司股份轉讓給誼和醫療或其指定的受讓方。控股股東擬變更。公司的實際控制人將由陳德康變更為林弘立、林弘遠兄弟。值得一提的是,2019年年度業績預盈,實現扭虧為盈。要知道在2017年業績大幅下滑後,2018年莎普愛思出現大幅虧損。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.